ASCO 2010: Phase 1 Study of SCH 900105, an Anti-Hepatocyte Growth Factor Monoclonal Antibody, as a Single Agent and in Combination with Erlotinib in Patients with Advanced Solid Tumors
TIVO-3: Final OS Analysis Of A Phase III, Randomized, Controlled, Multicenter, Open-Label Study To Compare Tivozanib To Sorafenib In Subjects With Metastatic Renal Cell Carcinoma (RCC)
